Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 07, 2024

SELL
$16.59 - $23.77 $3.36 Million - $4.82 Million
-202,689 Reduced 3.87%
5,028,350 $87.3 Million
Q3 2023

Nov 13, 2023

SELL
$16.59 - $23.77 $3.36 Million - $4.82 Million
-202,689 Reduced 3.87%
5,028,350 $87.3 Million
Q2 2023

Oct 07, 2024

SELL
$19.27 - $24.63 $26.8 Million - $34.3 Million
-1,391,416 Reduced 21.01%
5,231,039 $109 Million
Q2 2023

Aug 14, 2023

SELL
$19.27 - $24.63 $26.8 Million - $34.3 Million
-1,391,416 Reduced 21.01%
5,231,039 $109 Million
Q1 2023

Oct 07, 2024

SELL
$21.42 - $32.08 $18 Million - $26.9 Million
-838,305 Reduced 11.24%
6,622,455 $156 Million
Q1 2023

May 12, 2023

SELL
$21.42 - $32.08 $18 Million - $26.9 Million
-838,305 Reduced 11.24%
6,622,455 $156 Million
Q4 2022

Oct 07, 2024

BUY
$23.31 - $28.61 $174 Million - $213 Million
7,460,760 New
7,460,760 $208 Million
Q4 2022

Feb 10, 2023

SELL
$23.31 - $28.61 $16.6 Million - $20.3 Million
-710,177 Reduced 8.69%
7,460,760 $208 Million
Q3 2022

Nov 14, 2022

SELL
$23.4 - $34.25 $9.49 Million - $13.9 Million
-405,502 Reduced 4.73%
8,170,937 $191 Million
Q2 2022

Aug 12, 2022

BUY
$31.66 - $38.9 $15.2 Million - $18.7 Million
481,549 Added 5.95%
8,576,439 $289 Million
Q1 2022

May 13, 2022

BUY
$30.45 - $39.36 $110 Million - $142 Million
3,619,655 Added 80.88%
8,094,890 $283 Million
Q4 2021

Feb 11, 2022

BUY
$28.67 - $37.13 $38.7 Million - $50.1 Million
1,349,077 Added 43.15%
4,475,235 $136 Million
Q3 2021

Nov 09, 2021

BUY
$28.63 - $35.64 $3.28 Million - $4.08 Million
114,458 Added 3.8%
3,126,158 $103 Million
Q2 2021

Aug 11, 2021

BUY
$28.45 - $38.0 $85.7 Million - $114 Million
3,011,700 New
3,011,700 $91.1 Million

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $4.17B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.